Observation of Liraglutide's Effect on Function of Pancreatic Islets β-Cell in Type 2 Diabetes
10.12259/j.issn.2095-610X.S20250219
- VernacularTitle:利拉鲁肽改善2型糖尿病胰岛β细胞功能的观察
- Author:
Yu CHANG
1
;
Li GUI
;
Ruonan LI
Author Information
1. 云南省第三人民医院内分泌科,云南 昆明 650011
- Keywords:
Type 2 diabetes;
Initial diagnosis;
Liraglutide;
β cellular function
- From:
Journal of Kunming Medical University
2025;46(2):134-140
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of the GLP-1 receptor agonist liraglutide on β-cell function in patients newly diagnosed with type 2 diabetes patients.Methods Type 2 diabetes patients diagnosed between March 2020 and March 2021 in the Endocrinology Department of Yunnan Provincial Third People's Hospital were recruited and randomly divided into an experimental group and a control group.The experimental group was treated with liraglutide,a GLP-1 receptor agonist,for 6 months,while the control group received treatment with non-GLP-1 receptor agonists for 6 months(monotherapy or dual therapy).Changes in Weight,BMI,FPG,PG,HbA1c,FINS,FC-P,HOMA-IR,and HOMA-β levels were observed and measured before treatment and at 3 and 6 months after treatment.Results A total of 92 patients were included in the clinical observation(45 in the experimental group and 47 in the control group).Compared to baseline,both groups showed significant reductions in FPG,2hPG,and HbA1c at 3 and 6 months after treatment(P<0.01).FINS,HOMA-IR,and HOMA-β improved compared to pre-treatment levels(P<0.05).BMI decreased in the experimental group(P<0.05),while it slightly increased in the control group,but the difference was not statistically significant(P>0.05).Compared to the control group,the experimental group showed a greater reduction in FPG and 2hPG from baseline after 6 months of treatment,with statistically significant differences(P<0.05).HbA1c showed a certain decrease,but the difference was not statistically significant(P>0.05).FC-P in the experimental group was superior to pre-treatment levels at both 3 and 6 months(P<0.05),while in the control group,FC-P was only improved at the end of 6 months of treatment(P<0.05).Conclusion Early use of GLP-1 analogs in the treatment of newly diagnosed type 2 diabetes,as opposed to non-GLP-1 analog regimens,can lead to better restoration of β-cell function,weight reduction,and effective improvment of insulin resistance.
